Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy.

Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96

Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19

Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 9.75

A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity (2001) 9.45

Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42

Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71

Bone morphogenetic proteins. Growth Factors (2004) 8.61

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev (2001) 7.60

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41

BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet (2004) 7.37

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26

Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09

Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature (2010) 6.87

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med (2005) 6.87

Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol (2007) 6.22

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90

Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol (2009) 4.31

Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res (2009) 3.66

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol (2004) 3.50

Generation of Bmpr/Alk3 conditional knockout mice. Genesis (2002) 2.71

Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31

Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res (2005) 1.49

Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother (2002) 1.47

CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood (2005) 1.38

FoxO: linking new signaling pathways. Mol Cell (2004) 1.37

Crosstalk between Wnt and bone morphogenic protein signaling: a turbulent relationship. Dev Dyn (2010) 1.33

Immunology beats cancer: a blueprint for successful translation. Nat Immunol (2012) 1.32

Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. J Immunol (2002) 1.27

BMP signaling is required for normal thymus development. J Immunol (2005) 1.27

Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle (2005) 1.20

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev (2002) 1.20

Structural studies of the TGF-βs and their receptors - insights into evolution of the TGF-β superfamily. FEBS Lett (2012) 1.16

Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur J Immunol (2010) 1.13

The developmentally regulated expression of Twisted gastrulation reveals a role for bone morphogenetic proteins in the control of T cell development. J Exp Med (2002) 1.09

Tumor associated regulatory dendritic cells. Semin Cancer Biol (2012) 1.08

The role of TGF-beta superfamily during T cell development: new insights. Immunol Lett (2007) 1.06

Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells. J Immunol (2009) 1.05

Foxp3-deficient regulatory T cells do not revert into conventional effector CD4+ T cells but constitute a unique cell subset. J Immunol (2009) 1.03

Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations. Cytokine Growth Factor Rev (2009) 0.97

Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells. Eur J Immunol (2007) 0.97

Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation. Eur J Immunol (2011) 0.96

Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91

Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine (2009) 0.90

The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice. Novartis Found Symp (2004) 0.87

TCR repertoire and Foxp3 expression define functionally distinct subsets of CD4+ regulatory T cells. J Immunol (2009) 0.85

Suppression of immune surveillance in melanoma. Med Hypotheses (2001) 0.84

Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8. Oncogene (2011) 0.83

Comprehensive analysis of TGF-β and BMP receptor interactomes. Eur J Cell Biol (2011) 0.83

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genet Cytogenet (2007) 0.83

Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity (2007) 3.98

Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity (2006) 3.96

Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature (2013) 2.75

Peptide specificity of thymic selection of CD4+CD25+ T cells. J Immunol (2002) 1.31

Foxp3-deficient regulatory T cells do not revert into conventional effector CD4+ T cells but constitute a unique cell subset. J Immunol (2009) 1.03

Positive selection of a Qa-1-restricted T cell receptor with specificity for insulin. Immunity (2002) 1.00

Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells. PLoS One (2010) 0.87

SUMO1 regulates endothelial function by modulating the overall signals in favor of angiogenesis and homeostatic responses. Am J Transl Res (2013) 0.87

TCR repertoire and Foxp3 expression define functionally distinct subsets of CD4+ regulatory T cells. J Immunol (2009) 0.85

Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay. Biochem Pharmacol (2013) 0.83

Connexin 43 signaling enhances the generation of Foxp3+ regulatory T cells. J Immunol (2011) 0.81

Presentation of antagonist peptides to naive CD4+ T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells. Proc Natl Acad Sci U S A (2002) 0.79